Established in 1990, Raymedica^® is the pioneer and leader in all aspects of scientific and clinical experience with the use of Nucleus Arthroplasty™ motion preservation technology. The company is focused on the development and manufacture of spinal disc Nucleus Arthroplasty non-fusion technology to treat degenerative disc disease (DDD) and disc herniations, both of which can cause debilitating back and leg pain.

Raymedica’s philosophy is to:

• Create a total technology solution, not just a product.
• Devote ourselves to solid clinical outcomes.
• Expand our scientific, clinical, technological and regulatory expertise.
• Collaborate closely with our Surgeon and Scientific Advisory Councils.

Raymedica’s Leadership Position

• Over 4,600 patients implanted worldwide
• 1st nucleus replacement device to be approved for FDA IDE study
• 1st nucleus replacement device to receive CE-Mark
• More than 10 years of clinical experience, with some of the first patients implanted in 1996 still enjoying successful clinical outcomes
• More than 15 years of knowledge, research and expertise with hydrogel materials
• More than 500 pre-clinical tests
• Education leader with approximately 150 clinical papers and 81 posters
• Largest IP portfolio with 45 patents issued and 20 pending worldwide